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Abstract
Background: To determine complications during outpatient parenteral antimicrobial therapy (OPAT) administrated
through a peripheral venous line, PICC-line or PORT-A-CATH (PAC).
Methods: Catheter related complications in patients with cystic fibrosis during OPAT were identified through a
retrospective review of patient files supplemented by an interview.
Results: In 64 treatment episodes with a peripheral venous line, 51 (79.7 %) used bolus injection and 13 (20.3 %)
used infusion pump. 27 out of 51 (53.0 %) bolus injection episodes experienced complications, which required
removal. None were observed for infusion pump treatments.
The infectious complications requiring removal of peripheral venous line were 9 out of 23 (39.1 %) for the PICC line
and 11 out of 26 (42.3 %) for the PAC.
No anaphylaxis was observed during the OPAT treatments.
Conclusions: Our data indicate that using an infusion pump to administer the antibiotic treatment minimized
peripheral venous line complications. The frequency of complications leading to removal of the catheter is about
the same for PICC-lines and PACs, but the average life-time of the latter is much longer. Allergic reactions are not a
major problem.
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Background
Cystic fibrosis (CF) is a genetic disorder caused by muta-
tions in the CFTR gene, resulting in a multisystem dis-
ease dominated by pulmonary symptoms and the
establishment of chronic pulmonary infections with bac-
teria, e.g. Staphylococcus aureus, Haemophilus influen-
zae, and Pseudomonas aeruginosa. The infections and
the associated inflammatory responses are the most im-
portant causes of morbidity and mortality in CF patients
today. The chronic inflammation of the lungs leads to
bronchiectasia and lung fibrosis which eventually will
lead to respiratory failure [1, 2]. Effective treatment of
the pulmonary infections significantly reduces the deteri-
oration in lung function over time and increases life ex-
pectancy significantly [2].
In CF patients, antibiotic treatments are delivered by
three routes; intravenous, oral and as an inhaled aerosol
[3]. Patients who exhibit significant symptoms of pul-
monary exacerbation, e.g. fever and increased coughing,
will require intravenous antibiotic therapy especially if
infected with bacteria solely susceptible to antibiotics
which can only be administrated intravenously [4]. In
most instances lung function improves during the first
few days of treatment, but antibiotic treatment for 10 to
21 days is usually required in order to achieve the high-
est possible reduction in pulmonary bacterial load [4].
The option of outpatient parenteral antimicrobial ther-
apy (OPAT) [5] gives the CF patients an opportunity to
continue their daily life with minimal disruption while
undergoing antibiotic treatment essential for their qual-
ity of life. Furthermore OPAT reduces the risk of trans-
mission of bacteria between CF patients and reduces
isolation procedures at the hospital [6]. However, OPAT
does come with the challenge of ensuring that the
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patient delivers the right amount of antibiotics at the
right time without adverse reactions; Otherwise, the
therapy may fail or be unnecessarily prolonged [2, 3].
The focus of this study was to estimate the frequency of
the complications observed during and after OPAT
through a peripheral line (Bectorn Dickinson, Franklin
Lakes, NJ, United States of America) and through cen-
tral lines (PICC-line and PORT-A-CATH (PAC) among
CF patients followed at The Cystic Fibrosis Center West
at Aarhus University Hospital, Denmark.
Methods
Study protocol
A retrospective review was performed on the 167 CF pa-
tients followed at the Cystic Fibrosis Center at Aarhus
University Hospital, Denmark, identifying patients who
received regular OPAT with peripheral or central intra-
venous lines (PICC-line and PORT-A-CATH (PAC)).
OPAT is defined as the actual period in which the pa-
tients receive their antibiotics, and line insertion refers
to the setting where the patients have their peripheral or
central intravenous lines (PICC-line and PAC) in place
regardless if treatment takes place. Complications ac-
crued during line insertions life-time, which may have
included multiple OPATs, were documented by review-
ing the patients’ files. Since some CF-patients had more
than one device implanted, the number of complications
were normalized relative to individual line insertions and
not treatments at such.
The study was part of the routine quality assurance pro-
gram of outpatient antibiotic treatment, OPAT scheme in
our department. According to Danish law, data from qual-
ity assurance schemes does not need approval by the sci-
entific ethical committee if the data are anonymized
before publication as is the case in this report.
Patients
We included 60 CF patients who received antibiotic
treatment using one or more of the following devices: a
peripheral intravenous line in 2012 and 2013 (n = 64), a
PICC-line in the period 2009 – 2013 (n = 23) and a PAC
in the period 2005 – 2013 (n = 26).
Questionnaire
The study used patient files combined with question-
naire driven patient interviews (33 patients, Additional
file 1) to capture complications relating to the implanted
lines leading to preterm removal of the catheter. The
interview was essential because complications with the
peripheral intravenous lines were not always registered
in the patient files. Patients were initially contacted by e-
mail and then by phone. After three messages on their
answering machine no further attempts were made to
contact the patients.
Statistical analysis
A Mann–Whitney test was used to compare the life-
time of the peripheral venous line.
Results
Peripheral intravenous line
A total of 95 line insertions were identified with the per-
ipheral intravenous line and complications were docu-
mented by an interview. A total of 21 patients with
peripheral intravenous line were interviewed covering 64
of the 95 line insertions in a two year period (2012 to
2013) and these 64 line insertions with the peripheral
intravenous line have been included in this review. The
age of the patients ranged from 3 to 27 years (median
18 years). The OPAT lasted between 7 and 25 days (me-
dian 14 days) corresponding to a total of 898 treatment
days. The antibiotics were administered either by bolus
injection or continuous administration by an elastomeric
infusion pump. Out of the 64 line insertions with the
peripheral intravenous line, 13 (20.3 %) used infusion
pumps for their antibiotics treatment and the remaining
51 (79.7 %) used bolus injections. The antibiotics as with
infusions were always tazocin (piperacillin/tazobactam
)/sulfobactam whereas the antibiotics used with bolus
administration were either meropenem, ceftazidin,
cufuroxim or tazocin/sulfobactam. The most commonly
used antibiotic was tazocin which was administrated to
48 % of the CF patients. Stratification by the life-time of
line insertions of the peripheral line based on the bolus
injection method showed that 21/51 (41.2 %) of the per-
ipheral lines had complications with a life-time of the
peripheral line of less than 5 days (Table 1), whereas all
13 OPAT using the infusion pumps had a life-time of
the peripheral line of at least 5 days. The median life
time of the infusion pumps were 7 days whereas the
bolus injections had a median life time of 5 days
(Table 1). However, the difference was not statistically
significant (p = 0.242). The most common causes for re-
placement of the peripheral venous access were blockage
or dislocation and pain while injecting (Table 2).
PICC-line
From 2009 to 2013, 23 line insertions with PICC-line
were recorded. The age of the patients ranged from 9 to
32 years (median 22 years). The catheter life-time ranged
from 1 to 201 days (median 17 days including planned
removal after antibiotic treatment). In 15 (65.2 %) line
insertions the PICC-line was scheduled for removal after
completion of OPAT but 3 (20.0 %) of these line inser-
tions were removed prematurely due to complications.
In 8 (34.8 %) line insertions the PICC-line was kept in
place after the end of OPAT but 6 (75.0 %) had to be re-
moved subsequently due to complications (Table 3). In
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total nine (39.1 %) of the 23 implanted PICC-lines were
removed due to complications (Tables 3 and 4).
Port-a-Cath, PAC
In the period 2005 to 2013, 26 line insertions with PAC
were recorded. The age of the patients ranged from 9 to
42 years (median 24 years). The life time for the PACs
that has been removed ranged from 109 to 3,379 days
(median 484). In the 15 patients currently having a PAC
implanted the age of the implant ranged from 4 to
3,154 days (median 738). The PAC was removed due to
complications in 42.3 % (Table 5) of the 26 line inser-
tions. The complications leading to removal of the
catheter were infections, cosmetic considerations, dis-
placements of the catheter, occlusion of the catheter
and one unknown cause of PAC removal (Table 6).
General experiences with OPAT
Out of a total of 113 line insertions used in connection
with antibiotic treatment 16 insertions gave rise to an al-
lergic or toxic reaction with 14 (12.4 %) occurring during
OPAT and 2 (1.8 %) at the initiation of the treatment in
the hospital. The reactions were rash, fever or vomiting
but no anaphylactic reactions were recorded. In
Denmark the administration of antibiotics in the OPAT
setting is performed by the patient or family members.
One part of the study looked at the CF-patients expe-
riences with preparation and storage of their antibiotics.
Only one patient was found to have a problem with the
antibiotics taking 35 min to dissolve and there was one
case where the drug crystallized in the infusion pump.
The patients using infusion pumps found them very
convenient because of the short preparation time prior
to administration, less utensils needed to mix the medi-
cine and consequently the procedure took up less space
in the household and generated less waste.
Many CF-patients with a PICC-line or PAC for OPAT
initially had a peripheral line. The primary reason for
the patient to switch to a PICC-line or PAC for OPAT
was the many problems they experienced with their per-
ipheral lines such as frequent dislocations or blockages
during treatment. Patients who chose PICC-line typically
did not want a more permanent device like the PAC and
the PICC-line gave them the possibility to remove the
intravenous access immediately after their antibiotic
treatment, which 15 (65.2 %) of the PICC-line users
chose to do. Patients choosing PICC-lines also found
them cosmetically more acceptable having the inserted
catheter on the upper arm instead of the peripheral line
on the dorsum of the hand. Two out of 23 (8.7 %)
PICC-line insertions were thought to be so painful that
the patient did not want a PICC-line implanted again
and therefore wanted to use the peripheral venous line
instead.
Discussion
With OPAT usually lasting between 10–21 days [4] it is
most convenient for the CF-patient if their peripheral
venous line does not need to be changed too often.
Therefore the CF-patients keep their peripheral venous
lines until they experience complications, e.g. pain or
blockage before replacing it. In this study we found that
the median life-time of the peripheral venous line using
an infusion pump was longer (7 versus 5 days) compared
to using a bolus injection. This could suggest that the
more constant flow of antibiotics with the infusion
pump might be less traumatic for the vein leading to a
prolonged life-time of the peripheral venous line. Never-
theless, the median life-time of the peripheral venous
line was found to be at least 5 days. This is longer than
the recommended replacement every 3–4 days by
Cheung et al. [7] and support observations by Lai [8]
suggesting that the peripheral venous line can stay in for
a longer period of time given the right circumstances.
Based on the research done by Lai [8] a peripheral line
lasting less than five days during OPAT was defined as a
complication and our results also support that peripheral
lines should last at least 5 days. The peripheral venous
lines are used by CF-patients for antibiotic treatment
and this might have a positive effect on the use-life of
the peripheral line (less risk of infection). Thirteen of 64
(20.3 %) line insertions only lasted 1–2 days and 8/64





of line insertions (%)
Life time of the peripheral venous line Range
(days)
Median
(days)1–2 days (%) 3–4 days (%) ≥5 days (%)
Infusion pump 13 (20.3) 0 (0.0) 0 (0.0) 13 (100.0) 5–7 7
Bolus injection 51 (79.7) 13 (25.5) 8 (15.7) 30 (58.8) 1–16 5
Total 64 (100.0) 13 (20.3) 8 (12.5) 43 (67.2) 1–16 7
Table 2 Peripheral venous line. Complications which resulted in
replacement
Reason for replacements (n=52) No. (%)
Infection 3 (5.8)
Pain while injecting 15 (28.8)
Blockage or dislocation 29 (55.8)
Fell out 5 (9.6)
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(12.5 %) lasted 3–4 days resulting in a total of 32.8 %
chance of complications necessitating the peripheral
venous line to be changed before five days. However,
none of the patients using infusion pumps on peripheral
lines experienced complications. Patients should con-
sider an alternative if their peripheral venous line has to
be changed too often or should consider changing ad-
ministration method since our research indicates that
use of an infusion pump seems to improve the life time
of the peripheral venous line. The alternative to a per-
ipheral venous line could be a more permanent solution
like a PICC-line or a PAC.
A total of 23 line insertions with the PICC-line were
registered over a period of 4 years. The life-time use of
PICC-lines is reported be used up to 6 months [7]. Tolo-
meo et al. [9] found complications which lead to re-
moval in 18 (29.5 %) of the implants with the median
life-time of 15 days. This compares to our study which
showed that 9 (39.1 %) of the PICC-lines were removed
due to complications after median life-time of 17 days.
However, most of our patients did not have complica-
tions during the actual OPAT and only 20.0 % were re-
moved because of complications during OPAT. The
majority 75.0 % of complications occurred while the
catheters remained in place after completion of OPAT.
The PICC-line is a suitable solution for patients not
wanting a permanent PAC. PICC-lines can be removed
after completed OPAT and 65.2 % chose to do this. Out
of the 34.8 % PICC-lines where the patients elected to
keep the line inserted after completed OPAT the median
life time was 55 days. However, the majority of the
PICC-lines had to be removed due to complications.
Our experience with the PICC-line does not indicate
that it is advantageous to keep the catheter inserted after
completed OPAT. Some patients do not consider the
PICC-line solution because they have heard that the
PICC-line insertions are painful but of the 23 line inser-
tions only 2caused the patient to not consider having a
new PICC-line inserted.
Out of a total of 26 PACs implanted over a period of
8 years, 11 (42.3 %) were removed due to various com-
plications with infection being the most common reason
for removal. The extent of catheter removals correspond
to that found by Munck et al. [10] who reported that
37 % of the catheters were removed due to complica-
tions. Compared with the study by Munck et al. [10], the
infection rate was approximately the same, however
Munck et al. [10] reported a higher percentage of cath-
eter occlusions 48 % compared to 18 % in our study. As
a long term solution the PAC could be a viable solution
with the total median life-time of the PAC was in our
study found to be at least 735 days with 15 (57.7 %) pa-
tients still having their PACs in place. In another study
the PAC was reported to stay intact for an average of up
to 5 years [11] and in our study we currently have a pa-
tient who has had the PAC for 3,154 days (almost
9 years).
Patients who do not consider the more permanent so-
lution explain that they are scared of thrombosis or oc-
clusion leading to more serious conditions. The data
from our study show that only 2/26 (7.7 %) of the PAC
were removed due to a thrombosis and 1/23 (4.3 %) of
the PICC-lines were removed due to occlusion of the
catheter. The data indicate that the risk of a thrombosis
or occlusions of the catheter with PAC or PICC-line are
relatively low.
Conclusions
Aiming for the best possible quality of life for the CF-
patients, OPAT was introduced and the goal is to
minimize the complications experienced during OPAT.
Table 3 PICC-line complications
PICC line insertions (n = 23) No. (%) Complications causing removal (%) Total treatment days Range (Days) Median (Days)
Removed when OPAT ended 15 (65.2) 3 (20.0) 160 1–28 14
PICC line kept in after OPAT 8 (34.8) 6 (75.0) 667 33–201 55
Total 23 (100.0) 9 (39.1) 827 1–201 17
Table 4 PICC line removals
Reason for removal (n = 9) No. (%)
Infection 2 (22.2)
Pain 2 (22.2)
No return flow 1 (11.1)
Occlusion of the catheter 1 (11.1)
Dislocation 1 (11.1)
Line breakage 1 (11.1)
Patient asked for removal 1 (11.1)
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This review quantitates the complications of different
types of line insertions. Which line insertion to choose
will also depend on how permanent the patient wants
the device to be as well as the consideration of how
often they are in need of antibiotic treatment [7]. OPAT
is very important to the patients’ quality of life and
everyone who was interviewed was glad that they had
the choice of OPAT. They all wanted it to be successful
to avoid being confined to the hospital in periods where
intravenous antibiotic treatment is needed. This been
said patients do experience problems and because anti-
biotic treatment is such an important part of their life
the amount of complications have a significant impact
on the time and energy they spend on their line inser-
tions. Therefore, with a better understanding of the
complications experienced with the different type if line
insertions and during OPAT it is hoped that OPAT can
be further improved.
Limitations of this study is that it was conducted as a
retrospective study reviewing complications experienced
in the OPAT setting over a period of limited duration
and that the sample size in the study was limited to 60
patients from only one of the two CF centers in
Denmark.
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Table 6 Port-a-Cath, PAC, removals
Reason for removal (n = 11) No. (%)
Infection 3 (27.3)
Cosmetic considerations 3 (27.3)
Displacement of the catheter 2 (18.2)
Thrombosis 2 (18.2)
Unknown causes 1 (9.1)
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